Omeros Corporation Grants Performance-Based Stock Options to CEO

8-K filing — OMEROS CORP (OMER)

Filed: 2026-10-30 AccNo: 0001552781-26-000531 Size: 270 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

Omeros shares are trading lower after the company announced that the EMA’s CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion adopted in June 2026.

Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros shares are trading lower Friday after the company announced that the EMA’s CHMP upheld its negative opinion on narsoplimab for TA-TMA.

Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Decision follows re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (AHEG) consisting of hematologists, statisticians, and transplant physicians, together with two

Cantor Fitzgerald Reiterates Overweight on Omeros, Maintains $22 Price Target

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Omeros (NASDAQ:OMER) with a Overweight and maintains $22 price target.